fogsprayhk
Nilotinib Capsules | CAS 641571-10-0 | High-Purity BCR-ABL Tyrosine Kinase Inhibitor
Product Description
Nilotinib Capsules (CAS 641571-10-0) are a high-purity formulation of a selective BCR-ABL tyrosine kinase inhibitor, widely used in preclinical leukemia research. Nilotinib selectively inhibits BCR-ABL fusion proteins, including mutated forms resistant to first-generation inhibitors, providing a robust tool for mechanistic studies of chronic myeloid leukemia (CML) and related hematologic malignancies.
Mechanism and Molecular Background
The BCR-ABL fusion protein, resulting from the Philadelphia chromosome translocation, drives constitutive tyrosine kinase activity, promoting uncontrolled proliferation and survival of leukemic cells. Nilotinib binds to the ATP-binding site of BCR-ABL, inhibiting its phosphorylation activity, and downstream signaling pathways such as MAPK, PI3K/Akt, and STAT5, ultimately inducing apoptosis and cell cycle arrest in leukemic cells.
The capsule formulation allows reproducible dosing in in vitro and in vivo preclinical models, maintaining high stability and consistent bioavailability. Researchers can model dose-dependent effects on cellular proliferation, apoptosis induction, and signaling modulation using Nilotinib Capsules.
Preclinical Research Applications
Nilotinib Capsules are used for multiple experimental setups:
Cellular Proliferation Assays: Quantifying growth inhibition in BCR-ABL-positive leukemia cell lines.
Nilotinib Capsules | CAS 641571-10-0 | High-Purity BCR-ABL Tyrosine Kinase Inhibitor
Product Description
Nilotinib Capsules (CAS 641571-10-0) are a high-purity formulation of a selective BCR-ABL tyrosine kinase inhibitor, widely used in preclinical leukemia research. Nilotinib selectively inhibits BCR-ABL fusion proteins, including mutated forms resistant to first-generation inhibitors, providing a robust tool for mechanistic studies of chronic myeloid leukemia (CML) and related hematologic malignancies.
Mechanism and Molecular Background
The BCR-ABL fusion protein, resulting from the Philadelphia chromosome translocation, drives constitutive tyrosine kinase activity, promoting uncontrolled proliferation and survival of leukemic cells. Nilotinib binds to the ATP-binding site of BCR-ABL, inhibiting its phosphorylation activity, and downstream signaling pathways such as MAPK, PI3K/Akt, and STAT5, ultimately inducing apoptosis and cell cycle arrest in leukemic cells.
The capsule formulation allows reproducible dosing in in vitro and in vivo preclinical models, maintaining high stability and consistent bioavailability. Researchers can model dose-dependent effects on cellular proliferation, apoptosis induction, and signaling modulation using Nilotinib Capsules.
Preclinical Research Applications
Nilotinib Capsules are used for multiple experimental setups:
Cellular Proliferation Assays: Quantifying growth inhibition in BCR-ABL-positive leukemia cell lines.